1. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420.
2. Center for Drug Evaluation and Research. Food and Drug Administration. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Available at: http://www.fda.gov/cder/guidance/3618fnl.pdf. Accessed August 2000.
3. Volpe DA, Ciavarella AB, Asafu-Adjaye EB, Ellison CD, Faustino PJ, Yu LX. Method suitability of a Caco-2 cell model for drug permeability classification [abstract]. AAPS Pharm Sci. 2001; 3(S 1). Available at: http://www.aapspharmaceutica.com/search/abstract_view. asp?id=385&ct=01Abstracts.
4. Owens RC, Ambrose PG. Clinical use of the fluoroquinolones. Med Clin North Am. 2000;84:1447–1469.
5. Hooper DC. Mode of action of fluoroquinolones. Drugs. 1999;58(suppl 2):6–10.